Featured Platforms
  


Custom Protein Generation

Mammalian- Derived Products

Microbial- Derived Products

Antibody Drug Conjugates

Bispecific Ab Platform

Technologies & Platforms

Latest News

2020/06/19
Embrace Change to Turn Challenges into Opportunities: WuXi Biologics Successfully Hosted the 2nd Investor Day

2020/06/17
WuXi Biologics Selected as Winner of the 2020 Top Graduate Employers Award in China

2020/06/16
WuXi Biologics (Suzhou) Received EMA GMP Certificate for Biosafety Testing

2020/06/09
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States

2020/05/28
WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories

2020/05/19
WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States

2020/04/30
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

2020/04/28
WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility

2020/04/22
WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany

2020/04/14
WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection

2020/03/27
WuXi Biologics Achieved Remarkable Results in 2019

2020/03/11
WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland

2020/02/25
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19

2020/02/24
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

2020/02/18
WuXi Biologics’ Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

2020/02/12
WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak

2020/01/29
WuXi Biologics Provides Operation Update Related to the Coronavirus Outbreak

2020/01/29
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus

2020/01/16
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

2020/01/09
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

2020/01/02
WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392

2019/12/23
WuXi Biologics Receives “Special Award to Investors in Ireland” from Asia Matters

2019/11/22
WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland

2019/11/19
WuXi Biologics Congratulates Tychan on the World’s First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers

 

See below for other press releases by year.

2020      2019      2018  2017  2016  2015  2014  2013  2012


 

Upcoming Events



Newsletter Archive

Click Here to visit our Newsletter Archive

 

BACK